Standard BioTools Inc.
HealthcareNASDAQ:LAB · NASDAQ Global Select
-$0.02 today
Vol 1.75M · Avg 2.92M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.7%
avg -33.9%
ROIC
-12.2%
avg -22.6%
ROA
-13.2%
avg -22.7%
Analysis
ROIC is currently the strongest return metric at -12.2% versus its period average of -22.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Egholm | President, Chief Executive Officer & Director | $1.81M | — | 63 | $6.60M | 1.69% |
Hanjoon Kim | Chief Financial Officer | $1.17M | — | 55 | $2.76M | 0.71% |
Sean Mackay | Chief Business Officer & Senior Vice President | $955,568.00 | — | 44 | $1.01M | 0.26% |
Jonathan Mickelsen | Vice President & Chief Accounting Officer | — | — | — | — | — |
Elizabeth R. Jensen | Chief Human Resources Officer | — | — | 52 | — | — |
Mike Musgnug | Senior Vice President & Chief Commercial Officer | — | — | — | — | — |
John Graziano | Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
24
$16.30M
Sells
0
$0.00
Net Sentiment
+$16.30M
Net buying
Most Active
Casdin Partners Master Fund, L.P.
24 transactions
1–10 of 24
Analysis
Insiders reported 24 buys worth $16.30M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $16.30M. Casdin Partners Master Fund, L.P. was the most active insider with 24 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +29.9% | -1.8% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +29.9% over three years. Forward estimates point to Revenue at -1.8% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Bioventus Inc.
NASDAQ:BVS
$576.54M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
So-Young International Inc.
NASDAQ:SY
$244.05M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages LAB?
Standard BioTools Inc. (LAB) lists 7 active executives. The top listed executive is Sean Mackay, Chief Business Officer & Senior Vice President.
Are LAB insiders buying or selling?
Recent insider activity shows net buying of $245.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.